PCSK9 and systemic lupus erythematosus: Regarding the lack of treatment modalities and studies for the elderly-onset SLE (Rovenský and Tuchynová, 2008; Fettig et al., 2013), our study could serve as prima facie evidence to guide adding PCSK9 inhibitors (i.e., evolocumab) for the elder population with a high risk of SLE, especially those accompanied with abnormally high levels of LDL cholesterol.